FY27 revenue growth of 30-40%
Management guided FY27 revenue growth of 30-40%, supported by robust order pipeline and product launches.
SENORESPHARMACEUTICALS / guidance tracker
Keep management guidance in view.
Senores Pharmaceuticals · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
FY27 PAT growth of 50-60%
PAT growth guided at 50-60% for FY27, driven by operating leverage and margin stability.
Upnar facility revenue of 80-100 crores in FY27
The acquired Upnar facility is expected to contribute 80-100 crores revenue in FY27, with commercial shipments already started.
Blended EBITDA margin of 29-31% for FY27
Management expects blended EBITDA margin to remain in the 29-31% range for FY27, with potential upside from Upnar ramp-up.